Antihyperglycemic effects of stevioside in type 2 diabetic subjects
Stevioside is present in the plant Stevia rebaudiana Bertoni (SrB). Extracts of SrB have been used for the treatment of diabetes in, for example, Brazil, although a positive effect on glucose metabolism has not been unequivocally demonstrated. We studied the acute effects of stevioside in type 2 dia...
Gespeichert in:
| Veröffentlicht in: | Metabolism, clinical and experimental clinical and experimental, 2004, Vol.53 (1), p.73-76 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 76 |
|---|---|
| container_issue | 1 |
| container_start_page | 73 |
| container_title | Metabolism, clinical and experimental |
| container_volume | 53 |
| creator | Gregersen, Søren Jeppesen, Per B Holst, Jens J Hermansen, Kjeld |
| description | Stevioside is present in the plant
Stevia rebaudiana Bertoni (SrB). Extracts of SrB have been used for the treatment of diabetes in, for example, Brazil, although a positive effect on glucose metabolism has not been unequivocally demonstrated. We studied the acute effects of stevioside in type 2 diabetic patients. We hypothesize that supplementation with stevioside to a test meal causes a reduction in postprandial blood glucose. Twelve type 2 diabetic patients were included in an acute, paired cross-over study. A standard test meal was supplemented with either 1 g of stevioside or 1 g of maize starch (control). Blood samples were drawn at 30 minutes before and for 240 minutes after ingestion of the test meal. Compared to control, stevioside reduced the incremental area under the glucose response curve by 18% (
P = .013). The insulinogenic index (AUC
i,insulin/AUC
i,glucose) was increased by approximately 40% by stevioside compared to control (
P < .001). Stevioside tended to decrease glucagon levels, while it did not significantly alter the area under the insulin, glucagon-like peptide 1, and glucose-dependent insulinotropic polypeptide curves. In conclusion, stevioside reduces postprandial blood glucose levels in type 2 diabetic patients, indicating beneficial effects on the glucose metabolism. Stevioside may be advantageous in the treatment of type 2 diabetes. |
| doi_str_mv | 10.1016/j.metabol.2003.07.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71601245</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0026049503003871</els_id><sourcerecordid>71601245</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-58972636febcc779a176a17e228700ba9bec46f9b96e307eba6b873bd65a3d943</originalsourceid><addsrcrecordid>eNqF0MtKxDAUgOEgio6jj6B0o7vWk6ZJ2pXI4A0G3Og6JOmpZuhlTFph3t4MU3DpImTzneTwE3JFIaNAxd0m63DUZmizHIBlIDOg7IgsKGd5WgqAY7IAyEUKRcXPyHkIGwCQshSn5IwWoqRlwRdk9dCP7mu3Rf_Z7ix2zibYNGjHkAxNEkb8cUNwNSauT8bIkjypnTY4Rhgms9nLC3LS6Dbg5XwvycfT4_vqJV2_Pb-uHtapLbgcU15WMhdMNGislbLSVIp4MM9LCWB0ZdAWoqlMJZCBRKOFKSUzteCa1VXBluT28O7WD98ThlF1LlhsW93jMAUlqQCaFzxCfoDWDyF4bNTWu077naKg9vXURs311L6eAqlivTh3PX8wmQ7rv6k5VwQ3M9DB6rbxurcu_DnOJeNiv-n9wWHM8ePQq2Ad9hZr52MxVQ_un1V-AfDLkBQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71601245</pqid></control><display><type>article</type><title>Antihyperglycemic effects of stevioside in type 2 diabetic subjects</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Gregersen, Søren ; Jeppesen, Per B ; Holst, Jens J ; Hermansen, Kjeld</creator><creatorcontrib>Gregersen, Søren ; Jeppesen, Per B ; Holst, Jens J ; Hermansen, Kjeld</creatorcontrib><description>Stevioside is present in the plant
Stevia rebaudiana Bertoni (SrB). Extracts of SrB have been used for the treatment of diabetes in, for example, Brazil, although a positive effect on glucose metabolism has not been unequivocally demonstrated. We studied the acute effects of stevioside in type 2 diabetic patients. We hypothesize that supplementation with stevioside to a test meal causes a reduction in postprandial blood glucose. Twelve type 2 diabetic patients were included in an acute, paired cross-over study. A standard test meal was supplemented with either 1 g of stevioside or 1 g of maize starch (control). Blood samples were drawn at 30 minutes before and for 240 minutes after ingestion of the test meal. Compared to control, stevioside reduced the incremental area under the glucose response curve by 18% (
P = .013). The insulinogenic index (AUC
i,insulin/AUC
i,glucose) was increased by approximately 40% by stevioside compared to control (
P < .001). Stevioside tended to decrease glucagon levels, while it did not significantly alter the area under the insulin, glucagon-like peptide 1, and glucose-dependent insulinotropic polypeptide curves. In conclusion, stevioside reduces postprandial blood glucose levels in type 2 diabetic patients, indicating beneficial effects on the glucose metabolism. Stevioside may be advantageous in the treatment of type 2 diabetes.</description><identifier>ISSN: 0026-0495</identifier><identifier>EISSN: 1532-8600</identifier><identifier>DOI: 10.1016/j.metabol.2003.07.013</identifier><identifier>PMID: 14681845</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Biological and medical sciences ; Blood Glucose - analysis ; Cross-Over Studies ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - urine ; Diabetes. Impaired glucose tolerance ; Diterpenes - administration & dosage ; Diterpenes - therapeutic use ; Diterpenes, Kaurane ; Diuresis ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Fatty Acids, Nonesterified - blood ; Female ; Food ; Gastric Inhibitory Polypeptide - blood ; Glucagon - blood ; Glucagon-Like Peptide 1 ; Glucosides - administration & dosage ; Glucosides - therapeutic use ; Glycated Hemoglobin A - analysis ; Glycosuria ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - therapeutic use ; Insulin - blood ; Kinetics ; Male ; Medical sciences ; Middle Aged ; Peptide Fragments - blood ; Placebos ; Protein Precursors - blood ; Triglycerides - blood</subject><ispartof>Metabolism, clinical and experimental, 2004, Vol.53 (1), p.73-76</ispartof><rights>2004 Elsevier Inc.</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-58972636febcc779a176a17e228700ba9bec46f9b96e307eba6b873bd65a3d943</citedby><cites>FETCH-LOGICAL-c457t-58972636febcc779a176a17e228700ba9bec46f9b96e307eba6b873bd65a3d943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0026049503003871$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,4010,27900,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15573564$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14681845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gregersen, Søren</creatorcontrib><creatorcontrib>Jeppesen, Per B</creatorcontrib><creatorcontrib>Holst, Jens J</creatorcontrib><creatorcontrib>Hermansen, Kjeld</creatorcontrib><title>Antihyperglycemic effects of stevioside in type 2 diabetic subjects</title><title>Metabolism, clinical and experimental</title><addtitle>Metabolism</addtitle><description>Stevioside is present in the plant
Stevia rebaudiana Bertoni (SrB). Extracts of SrB have been used for the treatment of diabetes in, for example, Brazil, although a positive effect on glucose metabolism has not been unequivocally demonstrated. We studied the acute effects of stevioside in type 2 diabetic patients. We hypothesize that supplementation with stevioside to a test meal causes a reduction in postprandial blood glucose. Twelve type 2 diabetic patients were included in an acute, paired cross-over study. A standard test meal was supplemented with either 1 g of stevioside or 1 g of maize starch (control). Blood samples were drawn at 30 minutes before and for 240 minutes after ingestion of the test meal. Compared to control, stevioside reduced the incremental area under the glucose response curve by 18% (
P = .013). The insulinogenic index (AUC
i,insulin/AUC
i,glucose) was increased by approximately 40% by stevioside compared to control (
P < .001). Stevioside tended to decrease glucagon levels, while it did not significantly alter the area under the insulin, glucagon-like peptide 1, and glucose-dependent insulinotropic polypeptide curves. In conclusion, stevioside reduces postprandial blood glucose levels in type 2 diabetic patients, indicating beneficial effects on the glucose metabolism. Stevioside may be advantageous in the treatment of type 2 diabetes.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - analysis</subject><subject>Cross-Over Studies</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - urine</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diterpenes - administration & dosage</subject><subject>Diterpenes - therapeutic use</subject><subject>Diterpenes, Kaurane</subject><subject>Diuresis</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Fatty Acids, Nonesterified - blood</subject><subject>Female</subject><subject>Food</subject><subject>Gastric Inhibitory Polypeptide - blood</subject><subject>Glucagon - blood</subject><subject>Glucagon-Like Peptide 1</subject><subject>Glucosides - administration & dosage</subject><subject>Glucosides - therapeutic use</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Glycosuria</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - blood</subject><subject>Kinetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Peptide Fragments - blood</subject><subject>Placebos</subject><subject>Protein Precursors - blood</subject><subject>Triglycerides - blood</subject><issn>0026-0495</issn><issn>1532-8600</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0MtKxDAUgOEgio6jj6B0o7vWk6ZJ2pXI4A0G3Og6JOmpZuhlTFph3t4MU3DpImTzneTwE3JFIaNAxd0m63DUZmizHIBlIDOg7IgsKGd5WgqAY7IAyEUKRcXPyHkIGwCQshSn5IwWoqRlwRdk9dCP7mu3Rf_Z7ix2zibYNGjHkAxNEkb8cUNwNSauT8bIkjypnTY4Rhgms9nLC3LS6Dbg5XwvycfT4_vqJV2_Pb-uHtapLbgcU15WMhdMNGislbLSVIp4MM9LCWB0ZdAWoqlMJZCBRKOFKSUzteCa1VXBluT28O7WD98ThlF1LlhsW93jMAUlqQCaFzxCfoDWDyF4bNTWu077naKg9vXURs311L6eAqlivTh3PX8wmQ7rv6k5VwQ3M9DB6rbxurcu_DnOJeNiv-n9wWHM8ePQq2Ad9hZr52MxVQ_un1V-AfDLkBQ</recordid><startdate>2004</startdate><enddate>2004</enddate><creator>Gregersen, Søren</creator><creator>Jeppesen, Per B</creator><creator>Holst, Jens J</creator><creator>Hermansen, Kjeld</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2004</creationdate><title>Antihyperglycemic effects of stevioside in type 2 diabetic subjects</title><author>Gregersen, Søren ; Jeppesen, Per B ; Holst, Jens J ; Hermansen, Kjeld</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-58972636febcc779a176a17e228700ba9bec46f9b96e307eba6b873bd65a3d943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - analysis</topic><topic>Cross-Over Studies</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - urine</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diterpenes - administration & dosage</topic><topic>Diterpenes - therapeutic use</topic><topic>Diterpenes, Kaurane</topic><topic>Diuresis</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Fatty Acids, Nonesterified - blood</topic><topic>Female</topic><topic>Food</topic><topic>Gastric Inhibitory Polypeptide - blood</topic><topic>Glucagon - blood</topic><topic>Glucagon-Like Peptide 1</topic><topic>Glucosides - administration & dosage</topic><topic>Glucosides - therapeutic use</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Glycosuria</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - blood</topic><topic>Kinetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Peptide Fragments - blood</topic><topic>Placebos</topic><topic>Protein Precursors - blood</topic><topic>Triglycerides - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gregersen, Søren</creatorcontrib><creatorcontrib>Jeppesen, Per B</creatorcontrib><creatorcontrib>Holst, Jens J</creatorcontrib><creatorcontrib>Hermansen, Kjeld</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Metabolism, clinical and experimental</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gregersen, Søren</au><au>Jeppesen, Per B</au><au>Holst, Jens J</au><au>Hermansen, Kjeld</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antihyperglycemic effects of stevioside in type 2 diabetic subjects</atitle><jtitle>Metabolism, clinical and experimental</jtitle><addtitle>Metabolism</addtitle><date>2004</date><risdate>2004</risdate><volume>53</volume><issue>1</issue><spage>73</spage><epage>76</epage><pages>73-76</pages><issn>0026-0495</issn><eissn>1532-8600</eissn><abstract>Stevioside is present in the plant
Stevia rebaudiana Bertoni (SrB). Extracts of SrB have been used for the treatment of diabetes in, for example, Brazil, although a positive effect on glucose metabolism has not been unequivocally demonstrated. We studied the acute effects of stevioside in type 2 diabetic patients. We hypothesize that supplementation with stevioside to a test meal causes a reduction in postprandial blood glucose. Twelve type 2 diabetic patients were included in an acute, paired cross-over study. A standard test meal was supplemented with either 1 g of stevioside or 1 g of maize starch (control). Blood samples were drawn at 30 minutes before and for 240 minutes after ingestion of the test meal. Compared to control, stevioside reduced the incremental area under the glucose response curve by 18% (
P = .013). The insulinogenic index (AUC
i,insulin/AUC
i,glucose) was increased by approximately 40% by stevioside compared to control (
P < .001). Stevioside tended to decrease glucagon levels, while it did not significantly alter the area under the insulin, glucagon-like peptide 1, and glucose-dependent insulinotropic polypeptide curves. In conclusion, stevioside reduces postprandial blood glucose levels in type 2 diabetic patients, indicating beneficial effects on the glucose metabolism. Stevioside may be advantageous in the treatment of type 2 diabetes.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>14681845</pmid><doi>10.1016/j.metabol.2003.07.013</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0026-0495 |
| ispartof | Metabolism, clinical and experimental, 2004, Vol.53 (1), p.73-76 |
| issn | 0026-0495 1532-8600 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71601245 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Biological and medical sciences Blood Glucose - analysis Cross-Over Studies Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - urine Diabetes. Impaired glucose tolerance Diterpenes - administration & dosage Diterpenes - therapeutic use Diterpenes, Kaurane Diuresis Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Fatty Acids, Nonesterified - blood Female Food Gastric Inhibitory Polypeptide - blood Glucagon - blood Glucagon-Like Peptide 1 Glucosides - administration & dosage Glucosides - therapeutic use Glycated Hemoglobin A - analysis Glycosuria Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - therapeutic use Insulin - blood Kinetics Male Medical sciences Middle Aged Peptide Fragments - blood Placebos Protein Precursors - blood Triglycerides - blood |
| title | Antihyperglycemic effects of stevioside in type 2 diabetic subjects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T22%3A39%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antihyperglycemic%20effects%20of%20stevioside%20in%20type%202%20diabetic%20subjects&rft.jtitle=Metabolism,%20clinical%20and%20experimental&rft.au=Gregersen,%20S%C3%B8ren&rft.date=2004&rft.volume=53&rft.issue=1&rft.spage=73&rft.epage=76&rft.pages=73-76&rft.issn=0026-0495&rft.eissn=1532-8600&rft_id=info:doi/10.1016/j.metabol.2003.07.013&rft_dat=%3Cproquest_cross%3E71601245%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71601245&rft_id=info:pmid/14681845&rft_els_id=S0026049503003871&rfr_iscdi=true |